Literature DB >> 6904257

Complement activation in Staphylococcus aureus bacteraemia.

A F Hallett, R Cooper.   

Abstract

Serum levels of complement components C3, C4 and factor B were measured in twenty-five patients with Staphylococcus aureus bacteraemia. The levels of C3 were depressed in nine patients, five of whom also had low C4 levels, indicating activation of complement via the classical pathway. Two patients with low C3 levels also had low factor B levels, one of these being in association with a low C4 level, which indicates activation of both the classical and alternative pathways, the latter being via the C3b feedback cycle. The protein A content of the S. aureus cultures, as shown by the indirect haemagglutination titre, was high in nine patients with C3 hypocomplementaemia. There was some correlation between the presence of a high protein A content of the S. aureus culture and a low serum C3 level in the patient. Some clinical evidence of immune complex disease was found in three patients. Complement activation in S. aureus bacteraemia is most likely due to complex formation resulting from the interaction between the Fc portion of IgG and staphylococcal protein A. These complexes may also result in clinical symptoms of immune complex disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6904257      PMCID: PMC1536978     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  "Protein A" from S. aureus. I. Pseudo-immune reaction with human gamma-globulin.

Authors:  A Forsgren; J Sjöquist
Journal:  J Immunol       Date:  1966-12       Impact factor: 5.422

2.  Acute diffuse glomerulonephritis in acute staphylococcal endocarditis.

Authors:  W H Tu; M A Shearn; J C Lee
Journal:  Ann Intern Med       Date:  1969-08       Impact factor: 25.391

3.  Sensitized sheep red cells as a reactant for Staphylococcus aureus protein A. Methodology and epidemiology with special reference to weakly reacting methicillin-resistant strains.

Authors:  S Winblad; C Ericson
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1973-02

4.  Consumption of human complement components by complexes of IgG with protein A of Staphylococcus aureus.

Authors:  G Stålenheim; O Götze; N R Cooper; J Sjöquist; H J Müller-Eberhard
Journal:  Immunochemistry       Date:  1973-08

5.  Immunochemical quantitation of antigens by single radial immunodiffusion.

Authors:  G Mancini; A O Carbonara; J F Heremans
Journal:  Immunochemistry       Date:  1965-09

Review 6.  Clinical applications of complement assays.

Authors:  C A Alper; F S Rosen
Journal:  Adv Intern Med       Date:  1975

7.  Activation of the properdin pathway of complement in patients with gram-negative of bacteremia.

Authors:  D T Fearon; S Ruddy; P H Schur; W R McCabe
Journal:  N Engl J Med       Date:  1975-05-01       Impact factor: 91.245

8.  Teichoic acid antibodies in staphylococcal and nonstaphylococcal endocarditis.

Authors:  J G Crowder; A White
Journal:  Ann Intern Med       Date:  1972-07       Impact factor: 25.391

9.  Quatification of phagocytosis by human neutrophils. The use of radiolabelled staphylococcal protein A-IgG complexes.

Authors:  R Hälgren; G Stålenheim
Journal:  Immunology       Date:  1976-05       Impact factor: 7.397

10.  Teichoic acid antibodies in the diagnosis of serious infections with Staphylococcus aureus.

Authors:  C U Tuazon; J N Sheagren
Journal:  Ann Intern Med       Date:  1976-05       Impact factor: 25.391

View more
  2 in total

Review 1.  The Role of Macrophages in Staphylococcus aureus Infection.

Authors:  Grace R Pidwill; Josie F Gibson; Joby Cole; Stephen A Renshaw; Simon J Foster
Journal:  Front Immunol       Date:  2021-01-19       Impact factor: 7.561

Review 2.  The Role of the Oral Immune System in Oropharyngeal Candidiasis-Facilitated Invasion and Dissemination of Staphylococcus aureus.

Authors:  Raymond Pasman; Bastiaan P Krom; Sebastian A J Zaat; Stanley Brul
Journal:  Front Oral Health       Date:  2022-04-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.